Repligen | RGEN - Ebitda


Repligen reported $35.93M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agilent USD 466M 5M Jun/2025
Align Technology USD 203.61M 66M Jun/2025
Bio Techne USD 95.94M 19.64M Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Bruker USD 128.1M 27.1M Jun/2025
Charles River Laboratories USD 282.89M 64.81M Sep/2025
Danaher USD 2.13B 252M Dec/2025
Dentsply International USD 167M 30M Sep/2025
Exact Sciences USD 135.42M 2.8M Sep/2025
General Electric Aerospace USD 3.04B 185M Sep/2025
Henry Schein USD 295M 39M Sep/2025
Illumina USD 332M 12M Sep/2025
IQVIA Holdings USD 949M 39M Sep/2025
Mettler Toledo International USD 322.64M 26.75M Sep/2025
Myriad Genetics USD 10.3M 4.2M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Repligen USD 35.93M 3.75M Sep/2025
Revvity USD 248.91M 48.52M Dec/2025
Standard Biotools USD -16.54M 2.26M Sep/2025
Thermo Fisher Scientific USD 3.17B 335M Dec/2025
Waters USD 295.14M 18.87M Sep/2025
West Pharmaceutical Services USD 213.1M 14.6M Sep/2025